Phase 1 Study of OTS167 in Patients With Solid Tumors
Status:
Completed
Trial end date:
2016-05-04
Target enrollment:
Participant gender:
Summary
The purpose of this study is to test the safety and tolerability of an investigational drug
called OTS167. OTS167 is a maternal embryonic leucine zipper kinase (MELK) inhibitor which
demonstrated antitumor properties in laboratory tests. It is being developed as an
anti-cancer drug. In this first-in-human study OTS167 will be administered to patients with
solid tumors which have not responded to treatment.